ArticleTranslational andrology and urology2026
An interpretable LASSO-Boruta nomogram for non-muscle-invasive bladder cancer recurrence after intravesical instillation.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrence remains a major clinical challenge in non-muscle-invasive bladder cancer (NMIBC), highlighting the need for interpretable tools for individualized risk assessment. This study aimed to develop a transparent model that estimates recurrence risk in patients with NMIBC after transurethral resection of bladder tumor (TURBT) and intravesical instillation. Methods: We reviewed 200 patients with NMIBC who received TURBT and postoperative intravesical instillation at the Department of Urology, The Affiliated Hospital of Xuzhou Medical University, from January to December 2020. Recurrence status was determined from follow-up records. We collected baseline variables, preoperative laboratory results, and clinicopathological data. Patients were divided into training and validation sets (7:3). We screened predictors with multivariate Cox regression, least absolute shrinkage and selection operator (LASSO)-Cox regression, and Boruta analysis before building the nomogram. Model performance was checked with receiver operating characteristic (ROC) analysis, calibration curves, and decision curve analysis (DCA). Shapley additive explanations (SHAP) analysis was used for interpretation, and an R Shiny application was built. Results: Of the 200 patients, recurrence was observed in 90 cases. The final identified predictors were smoking, hypertension, hemoglobin (Hb), and serum Na. The nomogram showed stable performance, with time-dependent areas under the curves (AUCs) of 0.862, 0.918, and 0.948 in the training set and 0.725, 0.870, and 0.919 in the validation set at 12, 36, and 60 months, respectively. SHAP analysis ranked Hb as the main contributor; higher Hb and serum Na indicated lower recurrence risk, while smoking and hypertension indicated higher risk. Conclusions: This model provided internally validated recurrence-risk estimates; external validation and usability testing are required before clinical use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.